ANTX 1.06 AN2 Therapeutics, Inc.
| Range: | 0.87-22.22 | Vol Avg: | 601357 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | -0.22 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Mar 25 2022 | Empoloyees: | 41 | ||
| CUSIP: | 037326105 | CIK: | 0001880438 | ISIN: | US0373261058 | Country: | US |
| CEO: | Mr. Eric E. Easom | Website: | https://www.an2therapeutics.com | ||||
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Stock Details
ANTX 5
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
Joseph Schwartz·Wed Jul 03 2024
Leerink Partners
ANTX 2
AN2 Therapeutics (ANTX) PT Lowered to $2 at Evercore ISI
Liisa Bayko·Thu May 16 2024
Evercore ISI
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow